| Popis: |
Objective: Pulmonary vascular remodeling and inflammation play a major role in pulmonary arterial hypertension (PAH). Novel hematologic biomarkers have recently been recognized as a risk predictor for cardiovascular, oncologic, and inflammatory diseases. We aimed to investigate the association of hematologic biomarkers with mortality in PAH patients. Materials and Methods: Fourty-five patients diagnosed with PAH and 45 healthy volunteers were evaluated retrospectively. Concurrent data included clinical, echocardiographic, hemodynamic and hematologic variables. The study population was divided into subgroups based on admission neutrophil to lymphocyte ratio (NLR), neutrophil to monocyte ratio (NMR), platelet to lymphocyte ratio (PLR) values. Results: The median NMR and NLR levels were lower in healthy subjects than in PAH patients (7.7 (7-8.8) vs 9.2 (6.5-11.6); p= 0.03 and 1.9 (1.4-2.9) vs 2.6 (1.9-3.3); p= 0.04) respectively). The estimated mean survival duration was longer in patients with low NMR levels (93 (95% CI, 86-100) vs. 67 (95% CI, 45-88) months (p=0.006) respectively). NMR independently predicted poor outcome and improved the power of the other prognostic markers (OR 1.4 (95% CI, 1-1.8) p= 0.04); (AUC= 0.91; p< 0.0001). Conclusions: NMR levels alone or combined with other prognostic factors may predict mortality in patients with PAH. |
